Canaccord starts OrthoPediatrics with a Buy after guidance reset

As previously reported, Canaccord initiated coverage of OrthoPediatrics (KIDS) with a Buy rating and $24 price target OrthoPediatrics has established a “strong position” in the pediatric orthopedic device market, says the analyst. The firm sees the company’s recent guidance update, in which it lowered guidance for 2025 and established 12%-plus as a baseline for annualized growth, as a de-risking event that leaves room for upside.